Evidence map›Paper›PMID 34936050›Full record

ArticleNeurology and therapy2022

Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls.

Emma Viscidi, Maneesh Juneja, Jin Wang, Nasha Wang, Li Li, Wildon Farwell, Ishir Bhan, Corinne Makepeace, Karen Laird, Varant Kupelian and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Journal of clinical medicine · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Emma ViscidiBiogen, 225 Binney Street, Cambridge, MA, 02142, USA. emma.viscidi@biogen.com.
Maneesh JunejaMJ Analytics Ltd, London, UK.
Jin WangBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Nasha WangBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Li LiBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Wildon FarwellBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Ishir BhanBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Corinne MakepeaceBiogen, Maidenhead, UK.
Karen LairdBiogen, Maidenhead, UK.
Varant KupelianBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Susan EatonBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Anne DilleyBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Susan HallBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is little information about survival of spinal muscular atrophy (SMA) patients into adulthood, in particular from population-based samples. We estimated and compared age-specific, all-cause mortality rates in patients with SMA and matched controls in a large, retrospective cohort study using electronic health records (EHRs) from the pre-treatment era.

methodsThe US Optum

resultsFive thousand one hundred seventy-nine SMA cases and 51,152 controls were analyzed. The overall hazard ratio comparing cases with controls was 1.76 (95% CI 1.63-1.90). In patients with SMA type III diagnostic codes only, the all-age mortality rate was 1059/100,000 PYs in cases and 603/100,000 PYs in controls. In older age groups (13-20, 21-30, 31-40, 41-50, 51-60, and > 60 years), age-specific mortality rates for cases consistently exceeded those of controls. Limitations of this study included the inability to confirm the SMA diagnosis or SMA type by genetic or clinical confirmation.

conclusionPatients with SMA of all ages, including adults and type III patients, had a higher all-cause mortality rate as compared to age-matched controls during the pre-treatment era.

Indexed as

All-cause mortalityReal-world dataSpinal muscular atrophyType III spinal muscular atrophy

Identifiers

PMID34936050
PMCPMC8857352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.